Patricia Cobo-Stark

This paper identifies a six-nucleotide miRNA motif that represses PKD1 and shows that disrupting it improves PKD1 dosage and reduces cyst growth in ADPKD models.

This study identifies enhancer and super-enhancer changes in PKD, showing their role in gene dysregulation and potential as therapeutic targets.

This study identifies cis-inhibition of PKD1 and PKD2 mRNAs via miR-17 in ADPKD and shows that disrupting this mechanism reduces cyst growth in multiple models.

The paper identifies miR-17 family as the primary driver of kidney cyst growth in ADPKD by showing anti-miR-17 treatment reduces cyst proliferation and alters key metabolic and inflammatory pathways.